<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690482</url>
  </required_header>
  <id_info>
    <org_study_id>D9831C00001</org_study_id>
    <nct_id>NCT00690482</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>Columbus</acronym>
  <official_title>A 4 Week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study efficacy and safety of AZD1981 in patients with Chronic
      Obstructive Pulmonary Disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Mean change in FEV1 from baseline to Week 4 (last measurement post dose used, if data missing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical COPD Questionnaire</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Mean change in Total CCQ from baseline to Week 4 (last measurement post dose used, if data missing). Scores for total CCQ range from 0 (low symptoms) to 6 (high symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Mean change in FVC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Vital Capacity</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Mean change in SVC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Mean change in IC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEF25%-75%</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Mean change in FEF25%-75% (forced expiratory flow between 25% and 75% of the FVC) from baseline to Week 4 (last measurement post dose used, if data missing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Symptom Sleep Score</measure>
    <time_frame>Baseline and 4-week treatment period average</time_frame>
    <description>Mean change in COPD symptom sleep score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom sleep score range from 0 (no symptoms) to 4 (no sleep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Symptom Breathing Score</measure>
    <time_frame>Baseline and 4-week treatment period average</time_frame>
    <description>Mean change in COPD symptom breathing score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom breathing score range from 0 (none) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Symptom Cough Score</measure>
    <time_frame>Baseline and 4-week treatment period average</time_frame>
    <description>Mean change in COPD symptom cough score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom cough score range from 0 (none) to 4 (almost constant).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Symptom Sputum Score</measure>
    <time_frame>Baseline and 4-week treatment period average</time_frame>
    <description>Mean change in COPD symptom sputum score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom sputum score range from 0 (none) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF (Peak Expiratory Flow) Morning</measure>
    <time_frame>Baseline and 4-week treatment period average</time_frame>
    <description>Mean change in PEF morning from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF (Peak Expiratory Flow) Evening</measure>
    <time_frame>Baseline and 4-week treatment period average</time_frame>
    <description>Mean change in PEF evening from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Use of Reliever</measure>
    <time_frame>Baseline and 4-week treatment period average</time_frame>
    <description>Mean change in Total use of reliever from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>Up to 4 Weeks</time_frame>
    <description>The number of participants that experienced at least one adverse event.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Moderate to Severe COPD</condition>
  <arm_group>
    <arm_group_label>AZD1981</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 Oral tablet, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral tablet, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>Oral tablet, twice daily</description>
    <arm_group_label>AZD1981</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Oral tablet, twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FEV1 between 30 and 80% of predicted normal value post-bronchodilator (GOLD stages 2
             and 3)

          -  Clinical diagnosis of COPD

        Exclusion Criteria:

          -  Other clinically relevant disease or disorders

          -  Exacerbation of COPD within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¶rgen Vestbo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor in Respiratory Medicine, Hvidovre, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Russe</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vaerlose</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Przemysl</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bojnice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liptovsky Hradok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=215&amp;filename=CSR-D9831C00001.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=215&amp;filename=CSR-D9831C00001.pdf</url>
    <description>CSR-D9831C00001.pdf</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <results_first_submitted>July 1, 2013</results_first_submitted>
  <results_first_submitted_qc>October 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2013</results_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>118 patients were allocated to treatment and 111 completed the study. First patient entered the study on 26 May 2008 and the last patient finished the study on 17 December 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD1981</title>
          <description>AZD1981 Oral tablet, twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo Oral tablet, twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrolment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intake of prohibited medicine</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrew consent at rand.day</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient randomised to placebo withdrew consent immediately after the first dose of investigational product on the day of randomisation. No clinical measurements were performed and no reports of AEs were received for this patient. Since the patient is non-informative both in terms of efficacy and safety, he has been excluded from the analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>AZD1981</title>
          <description>AZD1981 Oral tablet, twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo Oral tablet, twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" lower_limit="47" upper_limit="78"/>
                    <measurement group_id="B2" value="62.4" lower_limit="43" upper_limit="83"/>
                    <measurement group_id="B3" value="62.4" lower_limit="43" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1</title>
        <description>Mean change in FEV1 from baseline to Week 4 (last measurement post dose used, if data missing)</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1</title>
          <description>Mean change in FEV1 from baseline to Week 4 (last measurement post dose used, if data missing)</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="-0.810" lower_limit="-0.810" upper_limit="0.740"/>
                    <measurement group_id="O2" value="0.011" spread="-0.550" lower_limit="-0.550" upper_limit="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical COPD Questionnaire</title>
        <description>Mean change in Total CCQ from baseline to Week 4 (last measurement post dose used, if data missing). Scores for total CCQ range from 0 (low symptoms) to 6 (high symptoms).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical COPD Questionnaire</title>
          <description>Mean change in Total CCQ from baseline to Week 4 (last measurement post dose used, if data missing). Scores for total CCQ range from 0 (low symptoms) to 6 (high symptoms).</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.299" spread="-2.00" lower_limit="-2.00" upper_limit="1.30"/>
                    <measurement group_id="O2" value="-0.340" spread="-2.20" lower_limit="-2.20" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity</title>
        <description>Mean change in FVC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity</title>
          <description>Mean change in FVC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="-1.74" lower_limit="-1.74" upper_limit="0.840"/>
                    <measurement group_id="O2" value="-0.102" spread="-1.09" lower_limit="-1.09" upper_limit="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slow Vital Capacity</title>
        <description>Mean change in SVC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Slow Vital Capacity</title>
          <description>Mean change in SVC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="-1.03" lower_limit="-1.03" upper_limit="2.30"/>
                    <measurement group_id="O2" value="-0.009" spread="-1.60" lower_limit="-1.60" upper_limit="0.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity</title>
        <description>Mean change in IC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity</title>
          <description>Mean change in IC from baseline to Week 4 (last measurement post dose used, if data missing)</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="-0.960" lower_limit="-0.960" upper_limit="1.08"/>
                    <measurement group_id="O2" value="-0.110" spread="-1.39" lower_limit="-1.39" upper_limit="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEF25%-75%</title>
        <description>Mean change in FEF25%-75% (forced expiratory flow between 25% and 75% of the FVC) from baseline to Week 4 (last measurement post dose used, if data missing)</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>FEF25%-75%</title>
          <description>Mean change in FEF25%-75% (forced expiratory flow between 25% and 75% of the FVC) from baseline to Week 4 (last measurement post dose used, if data missing)</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L/s</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042" spread="-0.900" lower_limit="-0.900" upper_limit="0.440"/>
                    <measurement group_id="O2" value="0.060" spread="-0.640" lower_limit="-0.640" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Symptom Sleep Score</title>
        <description>Mean change in COPD symptom sleep score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom sleep score range from 0 (no symptoms) to 4 (no sleep).</description>
        <time_frame>Baseline and 4-week treatment period average</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Symptom Sleep Score</title>
          <description>Mean change in COPD symptom sleep score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom sleep score range from 0 (no symptoms) to 4 (no sleep).</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.147" spread="-1.55" lower_limit="-1.55" upper_limit="1.00"/>
                    <measurement group_id="O2" value="-0.047" spread="-1.75" lower_limit="-1.75" upper_limit="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Symptom Breathing Score</title>
        <description>Mean change in COPD symptom breathing score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom breathing score range from 0 (none) to 4 (severe).</description>
        <time_frame>Baseline and 4-week treatment period average</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Symptom Breathing Score</title>
          <description>Mean change in COPD symptom breathing score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom breathing score range from 0 (none) to 4 (severe).</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.280" spread="-2.07" lower_limit="-2.07" upper_limit="0.486"/>
                    <measurement group_id="O2" value="-0.137" spread="-1.41" lower_limit="-1.41" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Symptom Cough Score</title>
        <description>Mean change in COPD symptom cough score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom cough score range from 0 (none) to 4 (almost constant).</description>
        <time_frame>Baseline and 4-week treatment period average</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Symptom Cough Score</title>
          <description>Mean change in COPD symptom cough score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom cough score range from 0 (none) to 4 (almost constant).</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.202" spread="-2.09" lower_limit="-2.09" upper_limit="1.22"/>
                    <measurement group_id="O2" value="-0.124" spread="-1.79" lower_limit="-1.79" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Symptom Sputum Score</title>
        <description>Mean change in COPD symptom sputum score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom sputum score range from 0 (none) to 4 (severe).</description>
        <time_frame>Baseline and 4-week treatment period average</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Symptom Sputum Score</title>
          <description>Mean change in COPD symptom sputum score from baseline to treatment period average (calculated using all available data after randomisation for each patient). Scores for COPD symptom sputum score range from 0 (none) to 4 (severe).</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.300" spread="-1.50" lower_limit="-1.50" upper_limit="0.844"/>
                    <measurement group_id="O2" value="-0.290" spread="-1.58" lower_limit="-1.58" upper_limit="0.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF (Peak Expiratory Flow) Morning</title>
        <description>Mean change in PEF morning from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
        <time_frame>Baseline and 4-week treatment period average</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>PEF (Peak Expiratory Flow) Morning</title>
          <description>Mean change in PEF morning from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="-45.0" lower_limit="-45.0" upper_limit="113"/>
                    <measurement group_id="O2" value="4.54" spread="-37.2" lower_limit="-37.2" upper_limit="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF (Peak Expiratory Flow) Evening</title>
        <description>Mean change in PEF evening from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
        <time_frame>Baseline and 4-week treatment period average</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>PEF (Peak Expiratory Flow) Evening</title>
          <description>Mean change in PEF evening from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="-66.5" lower_limit="-66.5" upper_limit="115"/>
                    <measurement group_id="O2" value="5.73" spread="-35.1" lower_limit="-35.1" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Use of Reliever</title>
        <description>Mean change in Total use of reliever from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
        <time_frame>Baseline and 4-week treatment period average</time_frame>
        <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Use of Reliever</title>
          <description>Mean change in Total use of reliever from baseline to treatment period average (calculated using all available data after randomisation for each patient).</description>
          <population>The efficacy analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo. However, not all patients will have valid, non-missing values for a given outcome measure.</population>
          <units>Number of inhalations per day</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.330" spread="-7.64" lower_limit="-7.64" upper_limit="3.81"/>
                    <measurement group_id="O2" value="-0.139" spread="-3.69" lower_limit="-3.69" upper_limit="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event</title>
        <description>The number of participants that experienced at least one adverse event.</description>
        <time_frame>Up to 4 Weeks</time_frame>
        <population>The safety analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981 Oral tablet, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral tablet, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event</title>
          <description>The number of participants that experienced at least one adverse event.</description>
          <population>The safety analysis is based on 117 randomized patients, 61 on AZD1981 and 56 on placebo.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD1981</title>
          <description>AZD1981 Oral tablet, twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Oral tablet, twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11.1">CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Holt</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

